NCT01127750

Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients

A 4-month, Open-label, Multi-center Study to Explore Tolerability and Safety and Health Outcomes of FTY720 in Patients With Relapsing Forms of Multiple Sclerosis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 2,417 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study will assess tolerability and safety and health outcomes in relapsing MS patients taking FTY720.

Conditions

• Relapsing Multiple Sclerosis

Interventions

Type	Name	Description
DRUG	FTY720

Timeline

• Start date: 2010-05-01
• Primary completion: 2011-10-01
• Completion: 2011-10-01
• First posted: 2010-05-21
• Last updated: 2017-02-23

Locations

289 sites across 23 countries: Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, Germany, Greece, Hungary, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Russia, Slovakia, Spain, Sweden, Switzerland, Turkey (Türkiye), United Kingdom